Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Insulin vs Rosiglitazone in Type 2 Diabetes
NCT00427154Phase 3Terminated
- Sponsor
- Novo Nordisk
- Start
- Jan 2007
- Primary completion
- Mar 2008
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin human in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c at 26 weeks. Started Jan 2007; status: terminated.
02
Drugs
insulin human
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00427154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00427154.